Back

Efficacy and harms associated with polypills for primary and secondary prevention of cardiovascular disease: a systematic review and meta-analysis.

30 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hypertension pharmacotherapy updates Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Adrian V Hernandez

University of Connecticut, Storrs (United States of America)

3 More presentations in this session

Presentation thumbnail
Impact of systolic blood pressure on ischemic and bleeding events and the efficacy and safety of rivaroxaban monotherapy: a post-hoc analysis of the AFIRE trial
Doctor S. Yamanaka (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Genetic inhibition of angiopoietin-like protein 3, 4, and 8 on cardiovascular disease risk
Professor X. Hua (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Community pharmacist intervention to enhance adherence in patients initiating cardiovascular medication: the PHARM-ADHERE randomized controlled trial
Miss A. Watteyne (Ghent, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension pharmacotherapy updates

The Event

Event poster

ESC Congress 2025

30 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
The cardiovascular polypill: simplicity to tackle a complex problem
thumbnail
Congress Presentation
Polypill: a drug for everyone?
thumbnail
Congress Presentation
Novel preventive cardiology clinic associated with reduced risk of recurrent major adverse cardiovascular events for patients with prior acute coronary syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources